ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för orteronel. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

29 träffar

Bibliografisk träff 2024-03-23

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.

Parikh M, Tangen C, Hussain MHA, Gupta S, Callis S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng HH, Maughan BL, Zhang J, Pachynski RK, Bryce AH, Lin DW, Quinn DI, Lerner SP, Thompson IM, Dorff TB, Lara PN, Agarwal N.

Eur Urol Oncol · clinical trial, phase iii; research-article; randomized controlled trial; journal article · DOI 10.1016/j.euo.2024.03.001

Bibliografisk träff 2024-02-29

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.

Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N.

Prostate Cancer Prostatic Dis · clinical trial, phase iii; research support, u.s. gov't, p.h.s.; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1038/s41391-024-00813-3

Bibliografisk träff 2023-07-04

Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials.

Lee YS, Kim SH, Tae JH, Chang IH, Kim TH, Myung SC, Kim M, Nguyen TT, Choi J, Kim JH, Kim JW, Choi SY.

Prostate Int · research-article; journal article · DOI 10.1016/j.prnil.2023.06.003

Bibliografisk träff 2023-04-19

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.

Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, Agarwal N.

Eur Urol · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1016/j.eururo.2023.03.036

Bibliografisk träff 2022-04-21

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).

Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM, Quinn DI.

J Clin Oncol · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1200/jco.21.02517

Bibliografisk träff 2022-02-17

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?

Chen MK, Liang ZJ, Luo DS, Xue KY, Liao DY, Li Z, Yu Y, Chen ZS, Zhao SC.

Front Pharmacol · review-article; review; journal article · DOI 10.3389/fphar.2022.843110

Bibliografisk träff 2021-10-28

A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).

Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, Peacock N, Finney L, Hoekstra SJ, Shastry M, Hainsworth JD, Burris HA.

Clin Breast Cancer · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1016/j.clbc.2021.10.011

Bibliografisk träff 2021-07-15

Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.

Guengerich FP, McCarty KD, Chapman JG, Tateishi Y.

J Biol Chem · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jbc.2021.100969

Bibliografisk träff 2020-04-09

Multistep Binding of the Non-Steroidal Inhibitors Orteronel and Seviteronel to Human Cytochrome P450 17A1 and Relevance to Inhibition of Enzyme Activity.

Child SA, Guengerich FP.

J Med Chem · research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.9b01849

Bibliografisk träff 2019-05-09

Conformational selection dominates binding of steroids to human cytochrome P450 17A1.

Guengerich FP, Wilkey CJ, Glass SM, Reddish MJ.

J Biol Chem · research-article; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.ra119.008860

Bibliografisk träff 2017-04-03

Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.

Petrunak EM, Rogers SA, Aubé J, Scott EE.

Drug Metab Dispos · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1124/dmd.117.075317

Bibliografisk träff 2017-02-28

Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.

Roviello G, Pacifico C, Chiriacò G, Generali D.

Crit Rev Oncol Hematol · meta-analysis; journal article · DOI 10.1016/j.critrevonc.2017.02.023

Bibliografisk träff 2016-04-19

CYP17 inhibitors in prostate cancer: latest evidence and clinical potential.

Alex AB, Pal SK, Agarwal N.

Ther Adv Med Oncol · review-article; review; journal article · DOI 10.1177/1758834016642370

Bibliografisk träff 2016-04-04

Prolonged biochemical response after discontinuation of orteronel (TAK-700) in a patient with metastasized castration-resistant prostate cancer.

Manenschijn L, Hamberg P.

Acta Oncol · letter; case reports · DOI 10.3109/0284186x.2015.1118657

Bibliografisk träff 2016-01-08

Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study.

Suri A, Pusalkar S, Li Y, Prakash S.

Clin Pharmacol Drug Dev · clinical trial, phase i; journal article · DOI 10.1002/cpdd.234

Bibliografisk träff 2016-01-08

A Phase 1, Randomized, Single-Dose Crossover Pharmacokinetic Study to Investigate the Effect of Food Intake on Absorption of Orteronel (TAK-700) in Healthy Male Subjects.

Suri A, Pham T, MacLean DB.

Clin Pharmacol Drug Dev · clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/cpdd.233

Bibliografisk träff 2015-09-29

Pharmacokinetics and Urinary Excretion Mechanism of Orteronel (TAK-700), A Novel 17,20-Lyase Inhibitor, in Animals.

Goto A, Moriya Y, Takeuchi T, Mandai T, Tagawa Y, Kondo T, Asahi S.

Drug Res (Stuttg) · journal article · DOI 10.1055/s-0035-1564118

Bibliografisk träff 2015-07-09

Re: Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer that has Progressed during or after Docetaxel-Based Therapy: ELM-PC 5.

Taneja SS.

J Urol · comment; journal article · DOI 10.1016/j.juro.2015.07.010

Bibliografisk träff 2015-01-26

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.

Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R.

J Clin Oncol · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2014.56.5119

Bibliografisk träff 2015-01-04

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.

Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G.

Invest New Drugs · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-014-0199-x

Bibliografisk träff 2014-06-25

Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.

Hussain M, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ, Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation.

Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1158/1078-0432.ccr-14-0356

Bibliografisk träff 2014-01-13

Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.

Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB.

Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-13-2436

Bibliografisk träff 2013-07-12

Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.

Yamaoka M, Hara T, Araki H, Kaku T, Hitaka T, Tasaka A, Kusaka M.

J Steroid Biochem Mol Biol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jsbmb.2013.07.002

Bibliografisk träff 2013-06-21

Development and validation of an RP-HPLC method for the quantitation of Orteronel (TAK-700), a CYP17A1 enzyme inhibitor, in rat plasma and its application to a pharmacokinetic study.

Kumar A, S VK, Gurav S, Zainuddin M, Dewang P, Kethiri RR, Rajagopal S, Mullangi R.

Biomed Chromatogr · journal article · DOI 10.1002/bmc.2964

Bibliografisk träff 2012-11-09

Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.

Hara T, Kouno J, Kaku T, Takeuchi T, Kusaka M, Tasaka A, Yamaoka M.

J Steroid Biochem Mol Biol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jsbmb.2012.10.020

Bibliografisk träff 2012-06-19

Development and validation of an enantioselective LC-MS/MS method to quantify enantiomers of (±)-TAK-700 in rat plasma: lack of in vivo inversion of (+)-TAK-700 (Orteronel) to its antipode.

Gurav S, Police A, Zainuddin M, Punde RR, Dewang P, Chandregowda V, Kethiri RR, Rajagopal S, Mullangi R.

Biomed Chromatogr · journal article · DOI 10.1002/bmc.2764

Bibliografisk träff 2012-06-01

Development and validation of a highly sensitive LC-ESI-MS/MS method for the determination of Orteronel® (TAK-700) in rat plasma: application to a pharmacokinetic study.

Gurav S, Police A, Zainuddin M, Farooqui JH, Reddy G K, Kethiri RR, Rajagopal S, Mullangi R.

Bioanalysis · validation study; journal article · DOI 10.4155/bio.12.107

Bibliografisk träff 2012-01-12

Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.

Yamaoka M, Hara T, Hitaka T, Kaku T, Takeuchi T, Takahashi J, Asahi S, Miki H, Tasaka A, Kusaka M.

J Steroid Biochem Mol Biol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jsbmb.2012.01.001

Bibliografisk träff 2011-09-01

Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.

Kaku T, Hitaka T, Ojida A, Matsunaga N, Adachi M, Tanaka T, Hara T, Yamaoka M, Kusaka M, Okuda T, Asahi S, Furuya S, Tasaka A.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2011.08.066